Weekly Digest - November 2024
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
Weekly Digest - November 2024
13 Nov 2024: $20 Billion Market Breakthrough: IPA Pioneers High-Impact Antibody Development for Next-Generation ADC Cancer Therapies
- ImmunoPrecise Antibodies Ltd. (IPA) has achieved a significant breakthrough in cancer research, positioning itself in a market for cancer-targeting antibodies projected to reach $20.7 billion by 2028
- The TATX-112 program successfully targets TrkB, a protein associated with aggressive cancers, paving the way for promising candidates for further development
- IPA is developing two programs targeting TrkB: TATX-200 focuses on T cell engagers to enhance immune response, while TATX-112 aims to create antibodies for direct drug delivery to tumor cells.
- Recent advancements in TATX-112 suggest these antibodies can effectively infiltrate and eliminate TrkB-expressing cells, potentially improving treatment efficacy and safety
